Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer
Head & Neck2023Vol. 45(5), pp. 1255–1271
Citations Over TimeTop 15% of 2023 papers
Kourtney L. Kostecki, Mari Iida, Anne L. Wiley, Stanley Kimani, Bridget Mehall, Kaitlin Tetreault, Roxana Alexandridis, Menggang Yu, Seungpyo Hong, Ravi Salgia, Justine Y. Bruce, Raymond B. Birge, Paul M. Harari, Deric L. Wheeler
Abstract
This data indicates that simultaneous targeting of Axl and MerTK with INCB081776, either alone or in combination with anti-PDL1, slows tumor growth and creates a proinflammatory TIME in mouse models of HNC.
Related Papers
- → Axl-dependent signalling: a clinical update(2011)154 cited
- → The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer(2017)42 cited
- → Growth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome(2021)31 cited
- → Sustained Release of Gas6 via mPEG-PLGA Nanoparticles Enhances the Therapeutic Effects of MERTK Gene Therapy in RCS Rats(2021)9 cited
- Expression of Gas6 Receptors, Tyro3, Axl, and Mertk, in Oocytes and Embryos and Effects of Mertk RNAi on the Oocyte Maturation(2012)